

REPORT OF THE SUPERVISORY BOARD

Dear Shareholder,

In fiscal year 2023, the Supervisory Board properly fulfilled the tasks incumbent upon it according to the law, the Articles of Association, and the rules of procedure. It continuously monitored the Executive Board and advised it on its corporate management activities. The Supervisory Board was directly involved in all decisions of fundamental importance to the company.

The Executive Board regularly, promptly, and extensively informed the Supervisory Board about corporate planning, business performance, and strategic progress, as well as the Group's current situation.

The Chairman of the Supervisory Board was also regularly informed by the Chairman of the Executive Board outside Supervisory Board meetings about current developments and significant business transactions. Moreover, the Chairman of the Supervisory Board and the Chairman of the Executive Board regularly exchanged views on issues related to strategy, planning, general business development, the risk situation

and risk management, and compliance. A total of eleven meetings of the full Supervisory Board were held in the reporting period. Where necessary, decisions were made by circular resolution between the meetings. Two written resolutions were adopted in this form in fiscal year 2023. The Compensation Committee met three times in the reporting period, of which one meeting was held in person and two as video conferences. The Nomination Committee met nine times, of which six meetings were held in person and three as video conferences. The Audit Committee met eight times, one of which were held in person and seven of which were held by video conference. If necessary, the Supervisory Board also issued approvals by written procedure. Resolutions of fundamental importance were passed either on the basis of relevant documents or after direct discussions with the Executive Board. The attendance rate at the meetings of the Supervisory Board was 99%, and at the meetings of the Audit Committee, Compensation Committee and the Nomination Committee likewise 100% in each case. The following table discloses individualized participation.

Supervisory Board Members	Supervisory Board/ Meetings	Supervisory Board/ Attendance Rate	Audit Committee	Remuneration Committee	Nomination Committee
	Videoconf.: 5 Presence: 5		Videoconf.: 7 Presence: 1	Videoconf.: 2 Presence: 1	Videoconf.: 3 Presence: 6
Prof Dr Wolfgang Maennig (Chairman) until 7 June 2023	6/6	100%			
Dr Andreas Eckert (Chairman) since 7 June 2023	5/5	100%			
Prof Dr Helmut Grothe (Deputy Chairman)	11/11	100%	8/8		
Paola Eckert-Palvarini	10/11	91%			
Dr Edgar Löffler	11/11	100%		3/3	9/9
Frank Perschmann	11/11	100%		3/3	9/9
Albert Rupprecht	11/11	100%	8/8		
Total		99%	100%	100%	100%



DR ANDREAS ECKERT
Chairman of the Supervisory Board

KEY TOPICS ADDRESSED BY THE SUPERVISORY BOARD

The following key topics formed the focus of the individual Supervisory Board meetings:

At the meeting on 24 January 2023, the Executive Board mainly reported on the preliminary key figures for the fiscal year 2022, the economic situation and the current status of major projects. The Supervisory Board also discussed the declaration on compliance submitted within the framework of the Corporate Governance Code. Furthermore, the sustainability report was discussed.

The main subject of the meetings on the 23 and 29 March 2023 was the review of the annual financial statements and the combined management report for the Group and the company as well as the remuneration report. In addition, the Executive Board informed about the status of current projects. In addition, the company's risk report, which describes the most important risk positions and risk management in the Group, and the agenda for the 2023 Annual General Meeting were approved. In view of the further development of the company, the Supervisory Board discussed a change of legal form to a European Company (Societas Europaea, SE) and decided to propose a change of legal form to the Annual General Meeting.

The meetings on May 12 and 19, 2023 focused on the reorganization of the Executive Board announced in December 2022 and the associated Executive Board appointments.

The two meetings on June 7, 2023 focused in particular on the course of business and preparations for the Annual General Meeting as well as the election of the new Chairman of the Supervisory Board.

At the Supervisory Board meeting on July 4, 2023, the Supervisory Board primarily discussed the development of the subsidiary Pentixapharm AG under capital market and corporate law as well as possible indications for Ga-68 CXCR4.

The meeting on August 4, 2023 mainly focused on the refinancing of Pentixapharm AG and the ongoing business and projects.

The meeting on October 20, 2023 focused on the presentation and approval of the budget for financial years 2024–2028 and the presentation of the preliminary business figures for the third quarter of 2023. The discussions focused on the strategic direction of the Medical and Isotope Products segments and Pentixapharm. Against the backdrop of a focus on core competencies, the Executive Board presented the Supervisory Board measures for a possible split-off of Pentixapharm AG. In addition, a training session was held at the production site in Braunschweig focusing on the “Production of radiopharmaceuticals under GMP conditions”, and following a detailed discussion of corporate governance issues, the Executive Board and Supervisory Board also approved the updated declaration of conformity in accordance with Section 161 of the German Stock Corporation Act (AktG). Another topic was the annual self-assessment of the Supervisory Board.

At its meeting on November 14, 2023, the Supervisory Board concentrated in particular on the establishment of a 50:50 joint venture with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma) at the Jintan site (China).

Other key topics included personnel changes in the management team, such as the resignation of Dr Hakim Bouterfa from the Executive Board of Eckert & Ziegler AG and the planned move of the founder and Chairman of the Supervisory Board of Eckert & Ziegler AG, Dr Andreas Eckert, to the Executive Board of Pentixapharm AG in spring 2024.

COMMITTEE ACTIVITIES

Remuneration Committee

The members of the Remuneration Committee are:

- Dr Edgar Löffler
- Frank Perschmann

The Remuneration Committee met three times in the reporting period and focused in particular on the Executive Board contracts and the review of bonus and profit-sharing entitlements. The committee drew up an external and internal comparison of the appropriateness of Executive Board remuneration. It reviewed the remuneration report and recommended that the Supervisory Board approve it.

Audit Committee

The members of the Audit Committee are:

- Albert Rupprecht (Chairman)
- Prof Dr Helmut Grothe

The Audit Committee meets the requirements of Arts. 100(5) and 107(4) sentence 3 AktG, according to which at least one member must have expertise in the field of accounting and at least one other member must have expertise in the field of auditing, and according to which the members as a whole must be familiar with the sector in which the Company operates.

The Audit Committee met eight times in the financial year 2023. The meetings focused in particular on monitoring the accounting process and on issues relating to the effectiveness of the internal control system and its further development, the effectiveness of the risk management system, and the internal audit system.

The individual meetings of the Audit Committee also focused on the following topics:

At its meeting on January 18, 2023, the Audit Committee dealt with the preparatory work for the annual financial statements and the consolidated financial statements. It also focused on transactions with related parties and companies.

The meeting on February 17, 2023 focused on the annual financial statements, the consolidated financial statements and the remuneration report. The committee also dealt with the quality of the audit and the audit priorities for the annual financial statements. Another topic was the reporting in the management report with regard to the internal control system (ICS) and risk management system (RMS).

In addition to the annual and consolidated financial statements, the meeting on March 1, 2023 focused on the invitation to tender for the auditor to audit the 2023 financial year and the update of the declaration of compliance with regard to the ICS and RMS during the year.

At the meeting on March 16, 2023, the Audit Committee again dealt with the ICS and RMS as well as the dependency report, the valuation of intangible assets and the taxonomy.

The meeting on July 5, 2023 focused on the quality assessment of the audit, preparatory measures for the 2023 annual financial statements with the new auditor and the review and further development of the RMS.

At its meeting on August 25, 2023, the Audit Committee dealt in particular with the preparation of the 2023 annual financial statements, the relevant audit topics and the taxonomy. Other topics included the framework for non-audit services and the further development of the RMS, particularly with regard to an aggregated risk analysis, as well as training topics.

During the meeting on November 8, 2023, the auditor essentially reported on the status of the preliminary audits for the 2023 annual financial statements, with a particular focus on the planned split-off of Pentixapharm AG.

At the meeting on December 14, 2022, the Audit Committee dealt among other things with the independence of the auditor, further results of the preliminary audit, and the focus and schedule of the audit of the annual financial statements. Another topic of the meeting was the evaluation of the ICS.

In addition, the members of the Audit Committee regularly attended training sessions. In the reporting period, training focused on the topics of sustainability and risk analysis. These included, in particular, the regulatory requirements of CSRD/ESRS, materiality analysis and taxonomy reporting. In the area of risk analysis, extensive and practice-oriented training was provided on scenario analysis, Monte Carlo simulation and risk aggregation with the aim of using the results of a simulation to weigh up risk and return and carry out a risk-appropriate assessment.

Nomination Committee

The members of the Nomination Committee are

- Dr Edgar Löffler
- Frank Perschmann

The **Nomination Committee** held nine meetings in 2023. It dealt in detail with the restructuring of the Executive Board as of June 2023 and the changes to the Supervisory Board. In the second half of the year, the Nomination Committee worked on the termination of the Executive Board contract with Dr Hakim Bouterfa. In addition, a plan was initiated for the development of the Executive Board from 2025 onwards and the following years.

The Supervisory Board was kept regularly and comprehensively informed about the work of the committees.

CORPORATE GOVERNANCE PRINCIPLES

In the period under review, the Supervisory Board continued to deal with the further development of the standards of good and responsible corporate governance, taking into account the German Corporate Governance Code as amended on April 28, 2022. On December 3, 2023, the Executive Board and the Supervisory Board issued a new Declaration of Conformity with the German Corporate Governance Code. Additional details regarding Corporate Governance are available in the Group's Corporate Governance Report, which is published on the Group's website in connection with the Declaration on Compliance. In the period under review, there were no conflicts of interest among members of the Supervisory Board.

EFFICIENCY REVIEW

The Supervisory Board regularly evaluates how effective it is as a body as a whole and how its committees perform their duties. A comprehensive review was conducted in September 2023. The results were discussed by the Supervisory Board in October 2023. No significant deficiencies were identified. The next review is planned for the current financial year.

TRAINING AND CONTINUING EDUCATION

The members of the Supervisory Board are responsible for the training and continuing education measures required for their tasks, such as on changes in the legal framework, and are supported in this by the company. As part of specific training, an in-house information event on the manufacture of radiopharmaceuticals under GMP conditions was held in the reporting year. In addition, the Supervisory Board regularly informed itself about market developments in nuclear medicine, for example by attending congresses and trade fairs.

AUDIT OF THE ANNUAL FINANCIAL STATEMENTS 2023

The annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG, the consolidated financial statements of the Eckert & Ziegler Group, and the combined management report were audited, together with the accounting system, by the auditors appointed by the Annual General Meeting for fiscal year 2023, Mazars GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Berlin, Germany. The auditor has concluded that all legal requirements have been met and has granted an unqualified auditor's opinion. Furthermore, the auditor has concluded that the Executive Board has implemented the measures incumbent upon it pursuant to Section 91 (2) of the German Stock Corporation Act (Aktiengesetz, AktG) regarding the establishment of a risk-monitoring system in a suitable form and that this system is suitable for the early detection of developments that endanger the continued existence of the company as a going concern. In regard to the report presented by the Executive Board on the company's relationships to affiliated enterprises in accordance with Section 312 AktG (affiliated company report), the auditor has confirmed that the statements made in the report are correct and that the payments made by the company for the legal transactions listed in the report were not inappropriately high.

The annual financial statements, including the combined management report, the affiliated company report and the auditor's audit report, were submitted to the Supervisory Board. A representative of the auditor took part in the Supervisory Board's balance-sheet meeting on 19 March 2024 and reported on the key findings of the audit. The Supervisory Board acknowledged and approved the auditor's results.

Based on its subsequent examination, the Supervisory Board raises no objections against the audited annual financial statements, the combined management report and the affiliated company report, including the Executive Board's concluding statement. The Supervisory Board therefore approved the annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and the consolidated financial statements of the Eckert & Ziegler Group. The annual financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG are thereby adopted. The Supervisory Board concurs with the Executive Board's recommendation* on the appropriation of net profit.

PERSONNEL CHANGES IN THE EXECUTIVE BOARD AND SUPERVISORY BOARD

Prof Dr Wolfgang Maennig stepped down from the Supervisory Board of Eckert & Ziegler AG at the end of the Annual General Meeting on June 7, 2023. Since 7 June 2023, the company's founder, Dr Andreas Eckert, has been the new Chairman of the Supervisory Board. At the end of November 2023, Dr Andreas Eckert announced that he would resign from the Supervisory Board in spring 2024 in order to join the Executive Board of Pentixapharm AG and support the announced split-off. In light of the planned split-off of Pentixapharm AG, Dr Hakim Bouterfa, responsible for clinical development, left the Executive Board of Eckert & Ziegler AG at the end of December 31, 2023.

ACKNOWLEDGMENT

The Supervisory Board would like to thank the Executive Board and all employees for their outstanding performance in the financial year 2023.

Berlin, March 2024

For the Supervisory Board



DR ANDREAS ECKERT

Chairman of the Supervisory Board

**Following a comprehensive review, the Executive Board has submitted to the Supervisory Board an amended proposal for the appropriation of net profit compared to the proposal presented in the notes to the annual financial statements. This is the Executive Board's proposal for the appropriation of net profit in the amount of € 0.05 dividend per dividend-bearing share. The Supervisory Board has analyzed this proposal and agreed with this amended resolution proposal, so that reference is made in this report of the Supervisory Board to this amended proposal of the Executive Board for the appropriation of net profit. An announcement regarding this resolution on the appropriation of net profit was published on March 19, 2024.*